Parkinson Disease

The FDA has approved a scalpel-free method for the treatment of patients with Parkinson disease who experience tremors and are medication-resistant.

A large Asian population study supports the link between HCV and parkinsonism in that region, and associated treating HCV with reduced risk.

The inhaled INBRIJA therapy is indicated to treat 'off' episodes in patients taking carbidopa/levodopa.

There were no significant differences among tardive syndrome patients and healthy controls in either resting motor function or active motor function, and both group's symptoms improved with raised intensity.

The FDA’s post-marketing review concludes a five-month speculation which began when CNN reported the Acadia Pharmaceutical antipsychotic therapy was associated with more than 700 deaths of patients with Parkinson disease since June 2016.

A review of tardive dyskinesia epidemiology implicates newer "atypical" antipsychotics as well as older neuroleptics.

The symptoms of tardive dyskinesia and drug-induced parkinsonism can be remarkably similar, but an accurate diagnosis is critical when treatment for one condition may worsen the other.

If done ethically, the genetic database's collaboration with GSK could provide researchers what they really need to improve neurological care: the right patients in the right studies.

The FDA has granted an orphan drug designation to Asceneuron SA for ASN120290, for the treatment of progressive supranuclear palsy.

Researchers at Penn Medicine have found patients with more severe forms of neurodegenerative diseases possess more co-pathologies.

Trial patients' total maximal chorea score improved by 2 points in 8 weeks.

The variant was uncovered while researchers observed a bizarre case of siblings, each with multiple sclerosis and malignant melanoma.

85% of subjects also took antipsychotic medications, usually atypical agents.

No evidence of adverse events or significant safety concerns has surfaced.

Blinded rating of remotely monitored patients supported the drug’s efficacy.

A deeper look a the sole FDA-approved treatment for Tardive Dyskinesia.

Depression may be a very early symptom of Parkinson's disease, or a risk factor for the disease.

Parkinson's disease patients (PD) have significantly worse vision for low contrast images at close and far distances, according to findings published in the Journal of Parkinson's Disease. At far distances, the PD patients had deficient abilities viewing high contrast images, too.

Patients with Parkinson's disease frequently look for treatments that physicians consider alternative or complementary therapies.

Ability to differentiate between subtypes of frontotemporal lobar degeneration could accelerate research into the pathology and prevention of this disease and aid in the design of disease-modifying therapies.

DaTscanâ„¢ SPECT imaging can help physicians assess diagnostic category and improve diagnostic confidence for patients with dementia with Lewy bodies.

Dr. Bruce Miller previews what he will be discussing about frontotemporal dementia at the upcoming American Academy of Neurology Annual Meeting.